Overview

Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Status:
Not yet recruiting

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to study the combination of nivolumab and axatilimab in patients with relapsed/refractory classical Hodgkin Lymphoma. This study will mainly look at if the combination works as expected.

Phase:

Phase 2

Details

Lead Sponsor:

University of Utah

Collaborator:

Incyte Corporation

Treatments:

Nivolumab